Guggenheim reiterates Climb Bio stock rating on kidney drug data

Wedbush keeps Climb Bio (CLYM) as a top pick with a $25 target, citing strong clinical data and catalysts through 2027. The stock fell 14% after recent updates, but the firm sees misplaced investor concerns and highlights positive Phase 1 results for CLYM116, including a 33-day half-life and significant reductions in Gd-IgA1 and free APRIL.

Piper Sandler reiterated an Overweight rating and $40 price target for Climb Bio (CLYM) after data presentations at the American Society of Nephrology meeting. The firm highlighted positive Phase 1 data for CLYM116 and budoprutug, with key Phase 2 and 3 milestones expected in 2027. CLYM stock has fallen 18% in a week to $9.21, despite a 319% gain over the past year. Analysts maintain strong buy consensus with price targets ranging from $18 to $35.

Climb Bio reported Phase 2 data for budoprutug, showing a 70% mean reduction in PLA2R antibodies at Week 12. 38% of patients in the 200 mg cohort achieved immunologic remission. The 600 mg cohort showed 98% B-cell suppression at Week 4. The drug was well tolerated with no serious events. Additional data is expected in 2027, according to the company.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; addi

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

Climb Bio (CLYM) reported early Phase 2 data for budoprutug in pMN, showing B-cell depletion, antibody reduction, and immunologic remission at 12 weeks. Both 200 mg and 600 mg doses were generally well tolerated. The company expects further data in 2027.